胶质瘤PI3K/AKT/mTOR 信号通路靶向治疗研究进展(4)
[21] Galanis E，Buckner J C，Maurer M J，et al. Phase II trial of temsirolimus(CCI-779) in recurrent glioblastoma multiforme：A north central cancer treatment group study[J].Journal of Clinical Oncology Official Journal of the American Society of Clinical Oncology，2005，23(23)：5294-5304.
[22] Fan QW，Weiss WA.Inhibition of PI3K-Akt-mTOR signaling in glioblastoma by mTORC1/2 inhibitors[J]. Methods in Molecular Biology，2012，821(821)：349-359.
[23] Bagcionder T，Wakimoto H，Anderegg M，et al. A dual PI3K/mTOR inhibitor，PI-103， cooperates with stem cell-delivered TRAIL in experimental glioma models[J].Cancer Research，2011，71(1)：154-163.
[24] Garlich JR，De P，Dey N，et al. A vascular targeted pan phosphoinositide 3-Kinase inhibitor prodrug，SF1126，with antitumor and antiangiogenic activity[J]. Cancer Research，2008， 68(1)：206-215.
[25] Prasad G，Sottero T，Yang X，et al. Inhibition of PI3K/mTOR pathways in glioblastoma and implications for combination therapy with erlotinib，temozolomide，and radiation[J]. Neuro-Oncology，2011，13(4)：S67-S68.
(收稿日期：2016-08-15) (蔡奋忠 林雄哲)
[22] Fan QW，Weiss WA.Inhibition of PI3K-Akt-mTOR signaling in glioblastoma by mTORC1/2 inhibitors[J]. Methods in Molecular Biology，2012，821(821)：349-359.
[23] Bagcionder T，Wakimoto H，Anderegg M，et al. A dual PI3K/mTOR inhibitor，PI-103， cooperates with stem cell-delivered TRAIL in experimental glioma models[J].Cancer Research，2011，71(1)：154-163.
[24] Garlich JR，De P，Dey N，et al. A vascular targeted pan phosphoinositide 3-Kinase inhibitor prodrug，SF1126，with antitumor and antiangiogenic activity[J]. Cancer Research，2008， 68(1)：206-215.
[25] Prasad G，Sottero T，Yang X，et al. Inhibition of PI3K/mTOR pathways in glioblastoma and implications for combination therapy with erlotinib，temozolomide，and radiation[J]. Neuro-Oncology，2011，13(4)：S67-S68.
(收稿日期：2016-08-15) (蔡奋忠 林雄哲)